CAS: 100299-08-9; Potassium 5-(9-Methyl-4-Oxo-4H-Pyrido[1,2-A]Pyrimidin-3-yl)Tetrazol-2-Ide

该化合物是一种杆状细胞稳定器,主要用作预防过敏结膜炎的眼科解决方案,其行动机制包括阻止胸腔释放甲胺和其他煽动性调解器,从而减少眼部痒痒,红度和刺激;该复合物显示出对胸腔细胞的高度选择性,尽量减少系统性副作用;其钾盐配制可增强溶性和生物利用率,确保有效时期交付;Pemirolast Potassium因其迅速开始行动并持续有效而受到重视,使其适合急性和预防性使用;与其他眼科药物兼容,在混合疗法中具有灵活性.

结构式图片

欧盟法规

C&L通报

上下游产品

CAS号69372-19-6 吡嘧司特 | CAS号1603-40-3 2-氨基-3-甲基吡啶

合成工艺路线路线简述

    专利信息


    专利号:US-8734846-B2
    优先权日:2008-06-16
    标 题 :Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles
    发明人:ALI MIR M; HRKACH JEFF; ZALE STEPHEN E; ALVAREZ DE CIENFUEGOS LUIS
    权利人:BIND BIOSCIENCES INC
    摘要:This application provides nanoparticles and methods of making nanoparticles using pre-functionalized poly(ethylene glycol)(also referred to as PEG) as a macroinitiator for the synthesis of diblock copolymers. Ring opening polymerization yields the desired poly(ester)-poly (ethylene glycol)-targeting agent polymer that is used to impart targeting capability to therapeutic nanoparticles. This “polymerization fromâ€? approach typically employs precursors of the targeting agent wherein the reactivity of functional groups of the targeting agent is masked using protecting groups. Also described is a “coupling toâ€? that utilized the poly(ethylene glycol)-targeting agent conjugate where the targeting agent remains in its native un-protected form. This method uses “orthogonalâ€? chemistry that exhibit no cross reactivity towards functional groups typically found within targeting agents of interest.

    专利号:US-2007160574-A1
    优先权日:2000-04-12
    标题 :Design of CXC chemokine analogs for the treatment of human diseases
    发明人:MERZOUK AHMED; SALARI HASSAN
    权利人:MERZOUK AHMED; SALARI HASSAN
    摘要:The present invention generally relates to the design, preparation, derivation, and use of mimetics of CXC chemokines (CXCL1-CXCL17) in the prevention, treatment, and ameliorization of a wide variety of diseases and disorders. Generally speaking, this invention is directed to the design, synthesis, and use of chemokine analogs which bind to CXC chemokine receptors CXCR1-CXCR7, such that the analogs can be designed to affect the activity of the receptor, either as an agonist or an antagonist. The analogs can be useful for treating a wide variety of diseases and disorders, and can also serve as an adjunct to the treatment of a variety of diseases and disorders.

    专利号:WO-2007079460-A3
    优先权日:2006-01-04
    标题:Design of cxc chemokine analogs for the treatment of human diseases
    发明人:MERZOUK AHMED; SALARI HASSAN
    权利人:CHEMOKINE THERAPEUTICS CORP; MERZOUK AHMED; SALARI HASSAN
    摘要:The present invention generally relates to the design, preparation, derivation, and use of mimetics of CXC chemokines (CXCL1-CXCL17) in the prevention, treatment, and ameliorization of a wide variety of diseases and disorders. Generally speaking, this invention is directed to the design, synthesis, and use of chemokine analogs which bind to CXC chemokine receptors CXCR1-CXCR7, such that the analogs can be designed to affect the activity of the receptor, either as an agonist or an antagonist. The analogs can be useful for treating a wide variety of diseases and disorders, and can also serve as an adjunct to the treatment of a variety of diseases and disorders.

    专利号:US-2014315720-A1
    优先权日:2012-10-24
    标 题 :Polysaccharide ester microspheres and methods and articles relating thereto
    发明人:FALLON DENIS G; GARRETT THOMAS S; KIZER LAWTON E; ZAZZARA KAREN L; COMBS MICHAEL T; JOHNSON RICHARD K; DEHART GARY
    权利人:CELANESE ACETATE LLC
    摘要:A method for producing a polysaccharide ester microsphere may include forming a polysaccharide ester product from a polysaccharide synthesis, wherein the polysaccharide ester product comprises a polysaccharide ester and a solvent; diluting the polysaccharide ester product, thereby yielding a polysaccharide ester dope; and forming a plurality of polysaccharide ester microspheres from the polysaccharide ester dope. Suitable polysaccharides may include, but are not limited to, starch, cellulose, hemicellulose, algenates, chitosan, and any combination thereof. Esters thereof may be organic esters (e.g., acetate and the like), inorganic esters (e.g., sulfonates and the like), or combinations thereof. Further, the solids conent of the polysaccharide ester dope, in some instances, may be greater than about 16 wt %.

    专利号:US-2012232031-A1
    优先权日:2009-10-19
    标 题:Injectable formulations for intra-articular or peri-articular administration
    发明人:HUTCHINSON JOHN HOWARD; PRASIT PETPIBOON PEPPI; DEARMOND ISABELLE MARGUERITE
    权利人:HUTCHINSON JOHN HOWARD; PRASIT PETPIBOON PEPPI; DEARMOND ISABELLE MARGUERITE; PANMIRA PHARMACEUTICALS LLC
    摘要:Described herein are injectable formulations for intra-articular or peri-articular administration, wherein the formulation is administered to treat joint pain. An injectable formulation for intra-articular or peri-articular administration disclosed herein comprises a therapeutically-effective amount of a leukotriene synthesis inhibitor compound formulated for intra-articular or peri-articular administration.
    江苏联环药业集团公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.lhpharma.com
    电话: 0514-87814842 87829556👤
    📞江苏联环药业集团公司 ⚠️参考联系方式

    销售电话:0514-87814842 87829556
    邮箱:xsb@lhpharma.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    国药集团国瑞药业有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.guorui.com.cn
    电话: 0554-6807095,0554-6809816👤
    📞国药集团国瑞药业有限公司 ⚠️参考联系方式

    销售电话:0554-6807095,0554-6809816
    邮箱:guorui@guorui.cn
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    郑州佰宇药业有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.zzbaiyu.com
    企业联系电话:13938569199👤
    📞郑州佰宇药业有限公司 ⚠️参考联系方式
    联系人:陈经理
    电话:13938569199


    邮箱:13938569199@163.com
    通信地址: 河南省郑州市新郑市龙湖镇小刘桥百鸿机电市场C3区22号
    邮编: 450000
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:河南省郑州市新郑市龙湖镇小刘桥百鸿机电市场C3区22号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    常州市庚鑫化工有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.czgxchem.com
    企业联系电话:13806140682👤
    📞常州市庚鑫化工有限公司 ⚠️参考联系方式
    联系人:张总
    电话:13806140682
    手机:13806140682

    邮箱:zhg@czgxchem.com
    通信地址: 江苏省常州市金坛区西门大街219-C1-117室
    邮编:
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:江苏省常州市金坛区西门大街219-C1-117室
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Tatsushima Y, Egashira N, Matsushita N, Kurobe K, Kawashiri T, Yano T, Oishi R. Pemirolast reduces cisplatin-induced kaolin intake in rats. Eur J Pharmacol. 2011 Jul 1;661(1-3):57-62. doi: 10.1016/j.ejphar.2011.04.026. Epub 2011 Apr 27. doi: 10.1055/s-0031-1296461. Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: a pooled analysis of two prospective, randomized, double-masked, placebo-controlled, phase III studies. J Ocul Pharmacol Ther. 2002 Oct;18(5):475-88. Japanese. Japanese. Japanese.

    合成参考文献


    摘要:Physicians Desk Reference. 58th ed. Thomson PDR. Montvale, NJ 2004., p. 3038
    摘要:
    参考文献:10.1159/000237363
    摘要:Minoda R, Masuyama K, Toriya T, Uno K, Eura M, Ishikawa T. Recurrent hearing impairment and nystagmus induced by repeated antigen exposure in actively sensitized guinea pigs. Int Arch Allergy Immunol. 1996 Oct;111(2):166–72. doi: 10.1159/000237363.
    参考文献:10.1055/s-0031-1296461
    摘要:Gohda T, Ra C, Hamada C, Tsuge T, Kawachi H, Tomino Y. Suppressive activity of pemirolast potassium, an antiallergic drug, on glomerulonephritis. Studies in glomerulonephritis model rats and in patients with chronic glomerulonephritis concurrently affected by allergic rhinitis. Arzneimittelforschung. 2008;58(1):18–23. doi: 10.1055/s-0031-1296461.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知